Thrombosis and Meningococcal Infection Rates in Pegcetacoplan Patients with Paroxysmal Nocturnal Hemoglobinuria in the Clinical Trial and Post‐Marketing Settings
Exposure‐Response Analyses of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Understanding the real-world clinical effectiveness of pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.
The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available fo rthe uses being investigated.
If you are a Healthcare Professional licensed to practice in the United States
If you are a Healthcare Professional licensed to practice in Canada
If you are a Healthcare Professional licensed to practice in Europe
If you are a Healthcare Professional licensed to practice in Australia